PTC Therapeutics Inc
PTCT
Company Profile
Business description
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
Contact
500 Warren Corporate Center Drive
WarrenNJ07059
USAT: +1 908 222-7000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
939
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.
stocks
Nvidia: Back in business in China; Raising fair value estimate
Nvidia is poised to become more dominant than ever as it is allowed to sell its key H20 GPUs in China.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,863.70 | 47.30 | 0.54% |
| CAC 40 | 7,722.09 | 44.12 | -0.57% |
| DAX 40 | 24,009.38 | 50.91 | -0.21% |
| Dow JONES (US) | 44,254.78 | 231.49 | 0.53% |
| FTSE 100 | 8,926.55 | 11.77 | -0.13% |
| HKSE | 24,514.44 | 3.32 | -0.01% |
| NASDAQ | 20,730.49 | 52.69 | 0.25% |
| Nikkei 225 | 39,728.48 | 65.08 | 0.16% |
| NZX 50 Index | 12,912.72 | 158.13 | 1.24% |
| S&P 500 | 6,263.70 | 19.94 | 0.32% |
| S&P/ASX 200 | 8,612.30 | 50.50 | 0.59% |
| SSE Composite Index | 3,506.94 | 3.16 | 0.09% |